Clinical Challenges: Avoiding Chemotherapy in Breast Ca
MedPage Today,
It's self-evident that being able to avoid the toxicity associated with chemotherapy is something all breast cancer patients…
It's self-evident that being able to avoid the toxicity associated with chemotherapy is something all breast cancer patients…
Routine use of the Oncotype DX recurrence score to personalize treatment of early breast cancer could reduce the first-year…
在過去,乳癌患者手術治療後,會進行一連串的化療以防止復發,但化療除了患者身體負擔與增加長期額外的健康風險外,費用也是一筆沈重的負擔。根據美國國家癌症研究所(2019)年4月發表的一項研究,診斷為早期乳癌的女性中,若進行基因檢測,可望大幅降低癌症治療的第一年費…
The use of cancer prognostic tests, such as Oncotype DX genetic testing, can lower the initial cost of early breast cancer care…
Cancer prognostic tests such as Oncotype DX and MammaPrint appear to lower the cost of breast cancer care in the US.
A study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S.
Using a specific genetic test in women diagnosed with early-stage breast cancer could reduce first year costs of cancer care in…
Personalizing breast cancer treatment based on Oncotype DX recurrence scores could result in small decreases in costs in the…
A new study suggests that Oncotype DX–guided treatment could reduce the cost for the first year of breast cancer care in the…
(HealthDay News) -- Personalizing breast cancer treatment based on Oncotype DX recurrence scores could result in small…
A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S.
-- Personalizing breast cancer treatment based on Oncotype DX recurrence scores could result in small decreases in costs in the…
A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S.
Source Newsroom: Georgetown Lombardi Comprehensive Cancer Center Share Credit: Genomic Health Cancer prognostic tests such as…
Cancer prognostic tests such as Oncotype DX and MammaPrint appear to lower the cost of breast cancer care in the US.
WASHINGTON -- A new studysuggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer…